Daily deaths (whole population) from COVID-19 in Nordic countries and Australia, from 2020 to 2024. The graphs demonstrate high mortality in Sweden in 2020 to 2021 in the prevaccination phase compared with border-sharing Norway and Finland, with Denmark, Iceland, and Australia. Note the different y-... More about this image found in Daily deaths (whole population) from COVID-19 in Nordic countries and Austr...

Figure 1. RELATIVITY-022 study design. ∗Part A dose-escalation cohort includes patients with R/R CLL, HL, certain non-HLs, and MM. The 800-mg dose was stopped because of futility. †Part C dose-escalation cohort includes patients with R/R HL and DLBCL. ‡Part B cohort expansion included patients w... More about this image found in RELATIVITY-022 study design. ∗Part A dose-escalation cohort includes patie...

Figure 2. Investigator-assessed PFS in part D patients. Patients with anti–PD-(L)1–naive HL (A) and anti–PD-(L)1–progressed HL (B). PFS for patients with DLBCL was not captured because of low patient numbers (<0), and also because these patients were heavily pretreated. Most patients had clas... More about this image found in Investigator-assessed PFS in part D patients. Patients with anti–PD-(L)1–n...

Figure 1. Characterization of TP53 mut MNs. (A) TP53 mut AML was highly prevalent followed by MDS-LB, -EB2, and -EB1, respectively. (B) The VAF was significantly higher in AML and MDS-EB2 compared with MDS-LB. (C) 17p loss was more prevalent in cases with single TP53 mut . (D) Most TP53... More about this image found in Characterization of TP53 mut MNs. (A) TP53 mut AML was highly preval...

Figure 2. Risk stratification of TP53 mut MN using CIT analysis. (A) The median OS for patients with TP53 mut MN was 8 months. (B) The median OS was progressively shorter with increasing blast percentage categories. (C) Patients with a TP53 mut VAF >8% had significantly poorer median... More about this image found in Risk stratification of TP53 mut MN using CIT analysis. (A) The median O...

Figure 3. Further stratification of TP53 mut MDS-LB by allelic status, CK, and VAF. (A) The median OS for patients with biallelic TP53 inactivation was significantly shorter compared with those with monoallelic inactivation. (B) Among patients with TP53 monoallelic inactivation, those wit... More about this image found in Further stratification of TP53 mut MDS-LB by allelic status, CK, and VAF...

Figure 4. Biological characteristics and survival in TP53 mut MDS-EB1 and -EB2 with VAF ≥10%. (A) The median OS of patients with MDS-EB1, MDS-EB2, and AML with a VAF ≥10% was significantly poor compared with those with a VAF <10%. (B) Patients with MDS-EB1, MDS-EB2, or AML with a VAF <1... More about this image found in Biological characteristics and survival in TP53 mut MDS-EB1 and -EB2 wit...

Figure 5. Survival outcome of TP53 mut AML was poor irrespective of allelic status and CK status. (A) The median OS of TP53 mut AML with VAF ≥10% was significantly poor compared with AML with a VAF <10%. (B) CK was more prevalent in AML cases with biallelic compared with those with mono... More about this image found in Survival outcome of TP53 mut AML was poor irrespective of allelic status...

Figure 6. Hierarchical classification schema for TP53 mut MNs. (A) The distribution of TP53 mut MN cases classified by WHO-5, ICC, and the proposed model. (B) The novel prognostic model identifies 4 distinct categories of TP53 mut MN with significant differences in survival outcomes. (C... More about this image found in Hierarchical classification schema for TP53 mut MNs. (A) The distributi...

The intestinal microbiome in patients receiving cellular therapy is influenced by multiple patient and disease-specific factors. Possible interventions may target different phases to promote beneficial microbiome-host interactions. More about this image found in The intestinal microbiome in patients receiving cellular therapy is influen...

Distribution of poor-risk TP53 mutant MDS/AML vs good-risk TP53 mutant MDS according to Shah et al (92% vs 8%). Poor-risk TP53 mutant MDS/AML is identified by patients with a biallelic/multihit disease, complex karyotype, and ≥5% bone marrow myeloblasts, with the good-risk TP53 mutant patien... More about this image found in Distribution of poor-risk TP53 mutant MDS/AML vs good-risk TP53 mutant ...